Search research articles
Contact Us
Filters
Showing results (311-320 of 489) with videos related to
Page
of 49
Sort By:
Cancer
|
October 15, 1990
Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy
N L Geller, T B Hakes, G R Petroni, et al.
Immunology Today
|
October 26, 2014
The stepwise activation of cytotoxic T lymphocytes
G Gromo, L Inverardi, R L Geller, et al.
Nucleic Acids Research
|
February 27, 2001
PCR candidate region mismatch scanning: adaptation to quantitative, high-throughput genotyping
M Beaulieu, G P Larson, L Geller, et al.
Human Heredity
|
April 2, 2005
On averaging power for genetic association and linkage studies
Gang Zheng, Jungnam Joo, Santhi K Ganesh, et al.
American Journal of Ophthalmology
|
November 30, 1999
Cost considerations of medical therapy for glaucoma
R G Fiscella, J L Geller, L L Gryz, et al.
Seminars in Oncology
|
October 1, 1990
Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer?
N L Geller, H I Scher, M K Parmar, et al.
Research in Nursing & Health
|
March 1, 1981
Catheter management programs and postoperative urinary dysfunction
M T Oberst, D Graham, N L Geller, et al.
Cancer Research
|
September 15, 1990
Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors
G C Toner, N L Geller, C Tan, et al.
The American Journal of Psychiatry
|
August 1, 1990
Second-generation deinstitutionalization, I: The impact of Brewster v. Dukakis on state hospital case mix
J L Geller, W H Fisher, J L Wirth-Cauchon, et al.
Annals of the New York Academy of Sciences
|
June 9, 1998
Use of an immunoisolation device for cell transplantation and tumor immunotherapy
R L Geller, T Loudovaris, S Neuenfeldt, et al.
Page
of 49
Search research articles
Search
Showing results (311-320 of 489) with videos related to
Sort By:
Page
of 49
Cancer
|
October 15, 1990
Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy
N L Geller, T B Hakes, G R Petroni, et al.
Immunology Today
|
October 26, 2014
The stepwise activation of cytotoxic T lymphocytes
G Gromo, L Inverardi, R L Geller, et al.
Nucleic Acids Research
|
February 27, 2001
PCR candidate region mismatch scanning: adaptation to quantitative, high-throughput genotyping
M Beaulieu, G P Larson, L Geller, et al.
Human Heredity
|
April 2, 2005
On averaging power for genetic association and linkage studies
Gang Zheng, Jungnam Joo, Santhi K Ganesh, et al.
American Journal of Ophthalmology
|
November 30, 1999
Cost considerations of medical therapy for glaucoma
R G Fiscella, J L Geller, L L Gryz, et al.
Seminars in Oncology
|
October 1, 1990
Can we combine available data to evaluate the effects of neoadjuvant chemotherapy for invasive bladder cancer?
N L Geller, H I Scher, M K Parmar, et al.
Research in Nursing & Health
|
March 1, 1981
Catheter management programs and postoperative urinary dysfunction
M T Oberst, D Graham, N L Geller, et al.
Cancer Research
|
September 15, 1990
Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors
G C Toner, N L Geller, C Tan, et al.
The American Journal of Psychiatry
|
August 1, 1990
Second-generation deinstitutionalization, I: The impact of Brewster v. Dukakis on state hospital case mix
J L Geller, W H Fisher, J L Wirth-Cauchon, et al.
Annals of the New York Academy of Sciences
|
June 9, 1998
Use of an immunoisolation device for cell transplantation and tumor immunotherapy
R L Geller, T Loudovaris, S Neuenfeldt, et al.
Page
of 49